Central nervous system involvement in gestational trophoblastic neoplasia

Ayhan A., TUNCER Z. S., Tanir M., Erbengi A.

Acta Obstetricia et Gynecologica Scandinavica, vol.75, no.6, pp.548-550, 1996 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 75 Issue: 6
  • Publication Date: 1996
  • Doi Number: 10.3109/00016349609054669
  • Journal Name: Acta Obstetricia et Gynecologica Scandinavica
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.548-550
  • Keywords: Brain involvement, Gestational trophoblastic neoplasia
  • Eskisehir Osmangazi University Affiliated: No


Background. To review the experience of seven cases of gestational trophoblastic neoplasia with central nervous system involvement. Methods. Seven patients among 50 cases of malignant gestational trophoblastic neoplasia were analyzed retrospectively in a single institution. Results. The mean age of the patients at diagnosis was 28.7 years (range: 20-34). While five of the patients presented initially with symptoms related to cranial involvement, the remaining two developed cerebral metastases during the therapy. In two patients, the presentation was so similar to a primary cranial pathology that craniotomy and biopsy revealed the trophoblastic involvement. The sites of involvement were the parietal lobe in three, temporal lobe in two and frontal lobe in two patients. Besides central nervous system involvement, four had additional lung and one had pelvic metastases. In terms of therapy, while five patients received methotrexate + actinomycin-D + cyclophospham regimen for 3 to 5 courses, only two could be administered additional intrathecal methotrexate. Since one patient exhibited a fulminant clinical course, she could not be delivered a chemotherapy regimen and was lost in two months of initial diagnosis. The other patient was administered modified Bagshawe protocol (5 courses) which was switched to etoposide + methotrexate-actinomycin-D + vincristine + cyclophosphamide (6 courses) due to development of resistance. She was still alive and free of disease after 24 months of initial diagnosis. Six of the patients were also delivered whole-brain irradiation simultaneously with chemotherapy. Conclusions. The prognosis of brain metastases still seems to be poor despite combination chemotherapy and radiotherapy. Measures should be focused on early diagnosis and prophylaxis.